Royalty Report: Drugs, Delivery, Pharmaceuticals – Collection: 29330


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Delivery
  • Pharmaceuticals
  • Drug Discovery
  • HIV / AIDs
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29330

License Grant
In consideration for the supplies of Material being provided by company hereunder, Licensor hereby grants to Licensee an exclusive option and right of first refusal to obtain a worldwide, exclusive License to make, have made, import, export, use, offer for sale and sell pharmaceutical products containing alpha interferon in combination with the Biphasix Technology, including without limitation, the Agreement Product (the Option).
License Property
Licensee may exercise the Option, in its sole discretion, at any time during the Option Period (as defined below), by providing Licensor with written notice to that effect.  The Option Period shall mean the period extending from the effective date until the date which is sixty (60) days after Licensee receives notice, as required under Section 8(a), of the successful completion of Phase III clinical trials for the Agreement Product under the Development Program.

Patents and Patent Applications (U.S.)
Application No.
Patent No. / Status
Biphasic Multilamellar Lipid Vesicles

Method for Preparing Biphasic Multilamellar Lipid Vesicles

Topical Patch for Liposomal Drug Delivery System
Composition and Method for Dermal and Transdermal Administration of a Cytokine
Biphasic Lipid Vesicle Composition for Transdermal Administration of an Immunogen

Composition for Transdermal and Dermal Administration of Interferon-alpha

Composition for Transdermal Administration of Insulin
Delivery of Polynucleotides Using Biphasic Lipid Vesicles

Field of Use
Field Topical alpha interferon formulations.

IPSCIO Record ID: 329658

License Grant
The Parties entered into an inter-company patent license agreement to license the development of the technology.
License Property
The program product is referred to as AP-001,  a topical Interferon a2b (IFN a2b) product for the treatment of Human Papiloma Virus (HPV) infection that can cause cervical cancer.

The technology involves the formation of biphasic lipid vesicles for use as a vehicle for administration of a biologically active material (BiPhasixâ„¢ Technology). The BiPhasixâ„¢ Technology is a novel encapsulation and delivery platform technology.

Field of Use
BiPhasix-encapsulated interferon IFN a2b is for use in treatment of HPV-cervical dysplasia.

IPSCIO Record ID: 367578

License Grant
Israeli Licensor hereby grants to the Licensee an exclusive worldwide through multiple tier license, in the Territory, to 1) the Intellectual Property Rights resulting from and/or arising under the Development Plan and/or Development Results including Resulting Patents, and/or the Drug Formulation and/or Product ; and 2) to make, have made, use, have used and/or license the Drug Formulation and/or the Development Results, and 3) to make, have made, sell, have sold, use, have used, license, and/or import Product; and 4) an exclusive license in the Territory to any Patents covering the Drug Formulation and Product to enable the Licensee to make, have made, sell, have sold, and/or use Products. The Licensee shall not use the Drug Formulation and/or the Development Results for any purpose other than exercise of the License. Licensor hereby grants to the Licensee a non-exclusive license, in the Territory under the Licensor Patents, to use the Licensor Formulation Technology to 1) develop, make, have made, and use, the Drug Formulation, and 2) develop, make, have made, sell, have sold, and use, Product.
License Property
Licensor Patents shall mean the patents and/or patent applications covering or disclosing Licensor Formulation Technology; and including but not limited to,  U.S. Patent No. 5,540,934, U.S. Patent No. 5,716,638 and PCT International Application No. PCT/EP95/02397 and any continuations, continuations-in-part, extensions, divisions, substitutions or additions to such applications and all patents which are reissues thereof, re-validations and registrations based thereon, and any and all foreign patents and patent applications corresponding thereto.

5,540,934 – Compositions for applying active substances to or through the skin
5,716,638 – Composition for applying active substances to or through the skin

Product means a pharmaceutical preparation or composition containing the Drug Formulation which is covered by a Valid Patent Claim.

Drug means the Licensees organoselenium drug or materials, as specified in this Agreement, and its racemate, metabolite, derivatives, isomers, polymorphs, crystals.

Drug Formulation means the formulation of the Drug utilizing Licensors Formulation Technology.

Field of Use
Field of use is for Ethosome, a non-invasive, transdermal drug delivery technology.

Ethosomes are phospholipid nanovesicles used for dermal and transdermal delivery of molecules.

IPSCIO Record ID: 291110

License Grant
Canadian Licensor hereby grants to Licensee an exclusive license for the Field in the Territory under the Licensed Patents; and an exclusive license for the Field in the Territory under the Know-How; for the sole purpose of developing, making, having made, importing, using, offering for sale and selling Licensed Product in the Territory, including the right to grant sublicenses under these rights as set out in this Agreement.
License Property
Licensed Product means Ciprofloxacin encapsulated in the Licensor Liposome Technology and which is intended for pulmonary delivery.

Ciprofloxacin means the chemical compound known as ciprofloxacin, whose more specified chemical name is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid and all pharmaceutically active salts thereof.

AERx Device means the durable hand-held device developed by Licensee for the delivery of Ciprofloxacin by inhalation and known as the AERx Device, as such device may be modified pursuant to the Agreement.

Loading Patents means the patents owned by University and exclusively licensed to Licensor and set out in Agreement.
5,800,833 – Method for loading lipid vesicles
5,785,987 – Method for loading lipid vesicles

Sphingosome Patents means the Patents owned by Licensor and set out in this Agreement.
5,543,152 – Sphingosomes for enhanced drug delivery

Licensed Patents means the Loading Patents and the Sphingosome Patents.

Patent means (a) all patent applications filed or having legal force in any country owned or controlled by Licensor as of the Effective Date; (b) all patents that have issued or in the future issue therefrom owned or controlled by Licensor as of the Effective Date, including without limitation utility, model and design patents and certificates of invention; and (c) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions (including supplemental protection certificates), additions, registrations or confirmations to or of any such patent applications and patents.

Licensor Liposome Technology means Licensor’s proprietary liposomal drug delivery system that encapsulates drugs in sphingomyelin/cholesterol liposomes using a proton gradient generated by either an ionophore or methylammonium sulfate.

Field of Use
This agreement pertains to patented liposomal formulation technology for the pulmonary delivery of ciprofloxacin

Ciprofloxacin is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body. It is used to treat different types of bacterial infections, including skin infections, bone and joint infections, respiratory or sinus infections, urinary tract infections, and certain types of diarrhea.

IPSCIO Record ID: 314332

License Grant
Licensor grants to the Licensee of Denmark and its Affiliates a worldwide, exclusive license, with the right to sublicense, to the Licensed Patents and Licensed Know-How, to research, develop, make, have made, use, import, export, sell, offer for sale, and otherwise transfer the Licensed Product in the Territory.

Licensee desires to obtain, and Licensor is willing to grant, an exclusive, worldwide license to the proprietary DepoFoam® delivery system in order to develop and commercialize  formulations of Liraglutide.

License Property
Licensor is a biopharmaceutical company specializing in the discovery, development and commercialization of DepoFoam® a proprietary injectable sustained-release delivery system (multivesicular liposomes).

Formulation Intellectual Property means all Know-How arising from activities performed under this Agreement regarding formulations of Liraglutide with DepoFoam and/or methods or processes for making or using such formulations.

Liraglutide means Licensees proprietary, human Glucagon-Like Peptide-1 (GLP-1} analogue.
Liraglutide is a medication used to treat diabetes mellitus type 2 and obesity.

Field of Use
DepoFoam is a drug delivery technology which consists of multi-vesicular liposome particles that contain internal chambers for encapsulated drugs. DepoFoam is capable of sustained release of a drug over a period of between one and 30 days. It works with narrow gauge needles and pen systems and offers flexible delivery that can be designed to for an immediate release dose followed by sustained delivery.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.